Investing.com - Rhythm Pharma (NASDAQ: RYTM) reported first quarter EPS of $-2.35, in line with the analyst estimate of $-2.35. Revenue for the quarter came in at $25.97M versus the consensus estimate of $27.02M.
Rhythm Pharma's stock price closed at $43.88. It is down -7.72% in the last 3 months and up 163.23% in the last 12 months.
Rhythm Pharma saw 0 positive EPS revisions and 3 negative EPS revisions in the last 90 days. See Rhythm Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Rhythm Pharma's Financial Health score is "good performance".
Check out Rhythm Pharma's recent earnings performance, and Rhythm Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar